News

Featured News

Flexibility, creativity, and dedication to make better therapeutics are at the heart of what we do. Read more on recent updates and highlights around our contract drug manufacturing activities.

Agilent logo featuring blue circular pattern on the left and company name in black text on the right, set against a white background.

Agilent Completes Acquisition of BIOVECTRA

September 20, 2024

SANTA CLARA, California, September 20, 2024 – Agilent Technologies Inc. (NYSE: A) today announced the company has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO) that specializes in biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics.[…]
 

Read More

  • Categories